Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Tiny, magnetic spheres may help overcome gene therapy hurdle

19.09.2002


The average person’s heart pumps about a gallon of blood per minute, a rate that can easily triple or quadruple during exercise.



The rapid flow of blood through the body is a major roadblock to the use of gene therapy to cure diseases. When injected into the blood, vector viruses – which carry corrective genes – tend to shoot past the target organ or tissue rather than sticking to it, like grains of sand moving past stones in a fast-flowing river.

Now, University of Florida gene therapy and biomedical engineering researchers have demonstrated a novel approach to the problem. In a July article in Molecular Therapy, they report attaching the adeno-associated virus, a widely used gene carrier, to the surface of tiny manufactured balls known as microspheres, each containing a miniscule particle of iron oxide. Using a magnet placed under culture dishes, the researchers were able to coax large amounts of the microspheres to target areas of the cultures. In related experiments in mice, the researchers showed the microspheres clung to cells or organs longer than the virus alone did.


The procedure, reminiscent of the toy that moves magnetized objects beneath transparent plastic, could someday evolve into a treatment that would enable doctors to guide corrective gene-containing microspheres injected into a patient with magnets placed outside the skin. Such procedures, could, for example, replace invasive catheterizations used to treat lung and heart diseases, the researchers said.

"By packaging the virus with the microsphere, we both guided it to the targeted area and got it to stick there," said Barry Byrne, the lead researcher and a pediatric cardiologist with the UF College of Medicine who is affiliated with the UF Genetics Institute.

Byrne and Cathryn Mah, an assistant research professor in the department of pediatrics, collaborated on the project with UF colleagues in pharmaceutics, genetics, and materials science and engineering. The effort, partially funded by the Whitaker Foundation, is part of UF’s growing biomedical engineering initiative involving a wide range of medical and engineering researchers.

Byrne said the adeno-associated virus, a virus that is an ideal gene carrier because it is not associated with any disease, is expensive and time consuming to manufacture in quantity. As a result, if it is ever to be widely used in treating disease, clinicians must have the ability to bind it specifically to the organ, tissue or cells they hope to treat, instead of having it dispersed through the body thus diminishing its effect.

"There is no way you could provide a systemic therapy spread throughout the body if you were only after the kidney, for example," said Byrne, of UF’s Powell Gene Therapy Center. "That even applies to dosing a mouse. Gene therapies are actually unachievable without some type of targeting."

It also is important to avoid unintentional release of therapeutic genes into reproductive cells in part so that engineered genes are not passed on to children, effectively altering the human genome, Byrne said. Proof that therapeutic genes do not spread beyond their targets – such dispersion could cause tumors in non-targeted cells – is one of the Food and Drug Administration’s main criteria for approving gene therapies, he said.

Mah said the UF team’s experiments were conducted over a period of about two years, much of that time devoted to the experiments in mice. In one experiment, the team injected the virus-coated microspheres into the tail veins of three mice and the free virus into the tail veins of three others. They monitored what happened by tracking "marker" proteins produced by the virus. The procedure was similar with cell cultures containing either the free virus or the virus-coated microspheres, with the researchers tracking the marker proteins through a technique called fluorescence microscopy, in which the proteins appear fluorescent green.

The results were impressive. The mice tail vein experiments revealed 10 times the expression of the marker protein in the target organ – the lung – than in other organs, indicating the microspheres both could be targeted and made to reside longer in their target than the free virus. In the cell cultures, meanwhile, the researchers achieved more than 100 times the expression of the marker protein in the magnetized areas of the culture versus the others.

"If you think about it in terms of making doses, it might take about six months to make a single-patient dose of this vector currently," Byrne said. "If this works, I’d say we could do it in four to six weeks or even less."

The microspheres used in the experiment were polystyrene, a type of plastic. In order for the spheres to be used in actual treatment, they would have to be made of biodegradable materials, said Chris Batich, a UF professor of materials science and engineering and biomedical engineering and member of the team. Although he said he has created such biodegradable microspheres since the project was first launched, they have yet to be tested. Among other challenges, researchers will have to prove the microspheres are harmless, efficient and predictable before they can be considered for use in clinical treatment, he said.

"You have to make sure they have the right properties," he said. "They have to have enough iron oxide to be pulled by the magnetic field, and you have to make sure they have the right rate of degradation, whether its two hours or two weeks."


Writer: Aaron Hoover, ahoover@ufl.edu
Sources: Barry Byrne, (352) 846-1531, bbyrne@ufl.edu
Chris Batich, (352) 392-6630,cbati@ufl.edu

Barry Byrne | EurekAlert!
Further information:
http://www.ufl.edu/

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

Bodyguards in the gut have a chemical weapon

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>